The impact of spironolactone on the severity of portal-systemic collaterals and hepatic encephalopathy in cirrhotic rats

Shao Jung Hsu, Sun Sang Wang, Teh Ia Huo, Fa Yauh Lee*, Hui Chun Huang, Ching Chih Chang, I. Fang Hsin, Hsin Ling Ho, Han Chieh Lin, Shou Dong Lee

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Liver cirrhosis and portal hypertension are accompanied by portal-systemic collaterals formation and lethal complications. Angiogenesis participates in the development of collaterals. Spironolactone is an aldosterone receptor antagonist used to control fluid overload in cirrhotic patients although recent studies suggest that it also inhibits angiogenesis. This study investigated the effect of spironolactone on abnormal angiogenesis and portal-systemic collaterals in cirrhosis. Liver cirrhosis was induced in Sprague-Dawley rats by common bile duct ligation (BDL), and sham-operated rats were the controls. The BDL and sham rats received spironolactone (20 mg/kg/d, oral gavage) or vehicle from day 15 to 28 after the operations. Spironolactone did not influence the portal and systemic hemodynamic, and the renal and hepatic biochemistry data, but it significantly ameliorated hepatic fibrosis, portal-systemic shunting, and mesenteric angiogenesis. Plasma vascular endothelial growth factor (VEGF) levels and the mesenteric protein expression of VEGF and phosphor-vascular endothelial growth factor receptor 2 (VEGFR-2) decreased in the spironolactone group. Spironolactone did not affect motor activity or plasma ammonia levels. The down-regulation of VEGF pathway participates, albeit partly, in the antiangiogenic effect of spironolactone. Thus, spironolactone treatment in patients with liver cirrhosis may provide additional benefits aside from ascites control.

Original languageEnglish
Pages (from-to)117-124
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume355
Issue number1
DOIs
StatePublished - 1 Oct 2015

Fingerprint

Dive into the research topics of 'The impact of spironolactone on the severity of portal-systemic collaterals and hepatic encephalopathy in cirrhotic rats'. Together they form a unique fingerprint.

Cite this